Medical News

RSS

Nintendo DS helps cure lazy eye

For six year old Ben Michaels nothing could be more welcome than his recent therapy regime. He was detected with a problem in his eyesight by a school nurse from the age of four. On examination he was found to have a lazy right eye or amblyopia. Left untreated it would have lost him his vision completely.

24 Jun 2010

e-Health identifiers for Australians to be allocated next week

The new Australian electronic healthcare database service has been on the cards for a while now. The legislation that flags off this scheme passed in the federal parliament and may be implemented next week on 1st July. This will ensure that every Australian is given a unique healthcare identification number. Doctors, hospitals, healthcare organisations and allied health providers will receive similar identifiers.

24 Jun 2010

Australian youth urged to become organ donors

New research has shown that many young Australians are not having their wishes to donate their organs honored because they fail to discuss these issues with their families beforehand. As a remedial measure Australia's chief medical officer, Professor Jim Bishop has urged more of the young population to come forth about their wishes to donate their organs after death.

24 Jun 2010

Patent application for tumor specific NPC-1C Antigen filed by Neogenix Oncology

Neogenix Oncology announced today that it has filed a patent application with the US Patent and Trade Office for the NPC-1C antigen. This antigen appears to be tumor specific for pancreatic and colorectal tumors.

24 Jun 2010

University of Michigan professor recognised with PHA Award of Excellence

The Pulmonary Hypertension Association (PHA) and Actelion Pharmaceuticals US, Inc., today announced Dr. Vallerie McLaughlin of the University of Michigan Health System as the recipient of the annual PHA Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care. As part of the award, the University of Michigan System will receive a grant in the amount of $50,000 to support continued excellence in care for patients with PAH.

24 Jun 2010

Cellonis' stem cells diabetes treatment helps reconstruct natural insulin production

Cellonis, a Beijing and HK-based biotech company, with its new personalized diabetes treatment concept has demonstrated an amazing improvement in their treated patients' conditions. The ongoing clinical study shows the treatment's best case could reconstruct a patient's natural insulin production and even reverse later complications like kidney failure. Treated patients may have the chance to return to the normal activities non-diabetes sufferers take for granted.

24 Jun 2010

USPTO grants Tethys key patent for PreDx Diabetes Risk Score test

Tethys Bioscience, Inc., a privately held company, announced today that the United States Patent and Trademark Office has granted the Company US Patent 7,723,050. The patent is directed to the company's groundbreaking PreDx™ Diabetes Risk Score (DRS) test and relates to proprietary methods for assessing the risk of developing a diabetic condition.

24 Jun 2010

Zetiq completes clinical trial of CellDetect technology for early identification of cervical cancer

Zetiq Technologies Ltd., a subsidiary of Bio-Light Ltd., reports the successful completion of another clinical trial to validate the effectiveness of the company's technology for early identification and diagnosis of cervical cancer, in conventional cytological smears.

24 Jun 2010

MonoSol Rx, Midatech collaborate to develop peptides for therapeutic delivery utilizing pharmaceutical films

MonoSol Rx, the developer of PharmFilm® drug delivery technology, today announced the expansion of its agreement with Midatech Group (Oxford, UK) to develop nanoparticle-based proteins and peptides for therapeutic delivery utilizing pharmaceutical films. Under the terms of the expanded agreement, MonoSol Rx has made an equity investment in Midatech and Keith Kendall, Executive Vice President and Chief Financial Officer of MonoSol Rx, will join the Midatech Board of Directors.

24 Jun 2010

Nektar commences dosing in Phase 1 study of NKTR-102 in combination with 5-FU/leucovorin

Nektar Therapeutics announced today that the first patients have been dosed in a new Phase 1 dose-escalation clinical study to evaluate NKTR-102, the company's lead oncology compound, in combination with 5-fluorouracil (5-FU)/leucovorin in refractory solid tumor cancers. The study is being conducted at University Hospitals Case Medical Center of the Case Comprehensive Cancer Center in Cleveland, Ohio.

24 Jun 2010

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck today announced plans to initiate a Phase II investigational proof-of-concept clinical study to evaluate its oral antifungal agent posaconazole for the treatment of chronic Chagas disease. Chagas disease results from infection with the parasite Trypanosoma cruzi that is spread by biting insects. The disease is estimated to affect approximately eight million people in Latin America, of whom approximately 30-40 percent will develop serious cardiac disease, digestive disease, or both as a result of this infection.

24 Jun 2010

Zilog launches ZMOTION Detection and Control solutions

Zilog, an IXYS company, and a trusted supplier of application specific, embedded micro controller (MCU) system-on-chip (SoC) solutions for industrial and consumer markets, today introduced its latest sensing and control technology for motion detection applications, including intrusion, security alarm industry, customer sensing and lighting control, medical patient monitoring, and other energy management applications.

24 Jun 2010

MDS Nordion, Guerbet, Cyceron collaborate to develop new PET radiotracers for cancer diagnostics

MDS Nordion, a leading provider of products and services to the global health science market, Guerbet, a pharmaceutical group specialized in medical imaging, and Cyceron, a biomedical imaging centre in France, announced today they have entered into an agreement to develop new Positron Emission Tomography (PET) radiotracers for cancer diagnostics.

24 Jun 2010

AGTC, Icagen complete agreement for purchase and sale of patent rights

AGTC, a privately held company, and Icagen, Inc. today announced the completion of an agreement for the purchase and sale of certain patent rights between the companies. Icagen is transferring its rights to patents relating to the ion channel gene CNGB3, which has been linked to certain disorders of the eye. Under the terms of the agreement, Icagen has assigned ownership of the patents to AGTC, which intends to use the patented technology for gene therapy as a potential treatment for Achromatopsia, a severe form of daytime blindness.

24 Jun 2010

Boston Scientific launches SCS lead splitters for use with Precision Plus Spinal Cord Stimulator System

Boston Scientific Corporation today announced U.S. Food and Drug Administration approval and launch of two spinal cord stimulation (SCS) lead splitters for use with its Precision Plus™ Spinal Cord Stimulator System, the world's first rechargeable SCS device for the management of chronic pain of the trunk, back and/or limbs.

24 Jun 2010

Infinity commences enrollment in IPI-493 Phase 1 clinical trial for advanced hematologic malignancies

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that patients are being enrolled in a Phase 1 clinical trial evaluating IPI-493 in patients with advanced hematologic malignancies. This multi-center study is the second clinical trial of IPI-493, Infinity's oral heat shock protein 90 (Hsp90) chaperone inhibitor.

24 Jun 2010

Cyanotech's revenues for fiscal 2010 increase 13%

Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for fiscal year 2010, ended March 31, 2010.

24 Jun 2010

St. Luke's joins Dr. John Goss in celebration of his 1,000th liver transplantation procedure

St. Luke's Episcopal Hospital (St. Luke's) joins John Goss, M.D., in celebrating his milestone as he recently performed his 1,000th liver transplantation procedure. The largest liver transplant program in Houston's world-renowned Texas Medical Center, St. Luke's performs approximately 75 liver transplants annually. Additionally, St. Luke's liver transplant survival rate is the highest in the nation, with a one-year adult patient survival rate of 96.5 percent compared to the national expected survival rate of 89.38 percent.

24 Jun 2010

BCBST achieves certification for implementation of CAQH CORE Phase II rules

CAQH announced today that BlueCross BlueShield of Tennessee has achieved certification for its implementation of the CAQH Committee on Operating Rules for Information Exchange Phase II rules. The certification will benefit more than 3 million insured members of the Tennessee health plan.

24 Jun 2010

LTCFP announces publication of revised guidebook, Long Term Care Insurance at the Worksite

Many companies seem conflicted by a key part of the recent Health Reform legislation, the CLASS Act, which will offer a form of long term care insurance for working people who may become disabled. "CLASS" stands for Community Living Assistance Services and Supports; and the program, a legacy of the late Senator Edward Kennedy, is intended to offer new choice and security for millions now at risk. But, "we find that those who manage employees or employee benefits don't know how to react," says Denise Gott, Chairman of the Board of LTC Financial Partners LLC, one of the nation's most experienced long term care insurance agencies.

24 Jun 2010

Medical News

Nintendo DS helps cure lazy eye

e-Health identifiers for Australians to be allocated next week

Australian youth urged to become organ donors

Patent application for tumor specific NPC-1C Antigen filed by Neogenix Oncology

University of Michigan professor recognised with PHA Award of Excellence

Cellonis' stem cells diabetes treatment helps reconstruct natural insulin production

USPTO grants Tethys key patent for PreDx Diabetes Risk Score test

Zetiq completes clinical trial of CellDetect technology for early identification of cervical cancer

MonoSol Rx, Midatech collaborate to develop peptides for therapeutic delivery utilizing pharmaceutical films

Nektar commences dosing in Phase 1 study of NKTR-102 in combination with 5-FU/leucovorin

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Zilog launches ZMOTION Detection and Control solutions

MDS Nordion, Guerbet, Cyceron collaborate to develop new PET radiotracers for cancer diagnostics

AGTC, Icagen complete agreement for purchase and sale of patent rights

Boston Scientific launches SCS lead splitters for use with Precision Plus Spinal Cord Stimulator System

Infinity commences enrollment in IPI-493 Phase 1 clinical trial for advanced hematologic malignancies

Cyanotech's revenues for fiscal 2010 increase 13%

St. Luke's joins Dr. John Goss in celebration of his 1,000th liver transplantation procedure

BCBST achieves certification for implementation of CAQH CORE Phase II rules

LTCFP announces publication of revised guidebook, Long Term Care Insurance at the Worksite

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News